2 Top Nasdaq Stocks to Buy Before They Soar in 2026

Nebius Group is up 73% in 2026 and Lam Research is up 54%, with both stocks benefiting from AI-driven demand. Nebius has secured $46 billion in deals with Meta and Microsoft and analysts expect revenue to rise more than sixfold this year, while Lam is seeing sustained demand for semiconductor equipment as capex at Micron and Samsung rises sharply. The article is constructive on both names and argues their growth trajectories can continue beyond 2026.

Analysis

The market is starting to separate AI “utility” winners from AI “model” winners. NBIS benefits from a scarcer asset: committed inference capacity with visible long-duration demand, which makes it less dependent on near-term model-cycle sentiment and more tied to enterprise workload migration. That said, its upside is increasingly a financing and execution story, not a pure demand story — once the market prices in the contracts, the next multiple leg depends on clean capacity ramp, customer concentration control, and avoiding dilutive capital raises.

LRCX is the cleaner second-order beneficiary because it sits one step upstream of the AI buildout. If hyperscaler capex stays elevated, the largest incremental winners are often the equipment names with leverage to both memory intensity and logic layering, especially when customers pull forward tool orders to de-risk supply. The subtle risk is that the consensus is underestimating how much of the current spending cycle is being funded by balance-sheet expansion at customers; if capex is front-loaded but end-demand normalizes, equipment bookings can peak before earnings do.

The broader read-through is supportive for META and MSFT, but more as demand absorbers than obvious trade expressions: they are effectively underwriting the next phase of AI infrastructure and can re-rate if inference monetization improves faster than depreciation ramps. MU is the key confirmation signal; if memory pricing tightens, it validates the depth of the AI spend cycle and extends the LRCX thesis. NVDA is not the best immediate relative-value expression here because the market already prices its centrality; the cleaner trade is on picks-and-shovels or on the under-owned inference layer.

Contrarian risk: the current move may be too linear on a 6-12 month horizon. AI spend can stay strong while equity returns compress if the market shifts from "growth at any price" to "proof of cash conversion," particularly under macro stress. The first sign of trouble would be a gap between capex headlines and revised forward revenue guides; if that happens, NBIS is the most vulnerable, while LRCX should be relatively resilient but not immune.

Key Decisions for Investors

• Long LRCX vs short NVDA, 3-6 month horizon: favor the lower-consensus beneficiary of sustained AI infrastructure spend over the crowded lead AI name; target 10-15% relative outperformance if capex revisions continue.
• Buy NBIS on pullbacks only, with a 1-3 month window: treat it as a high-beta contract-backed growth trade, but size tightly because upside depends on execution and external financing conditions; use a 15-20% downside stop.
• Pair long LRCX / short a basket of weaker semiconductor equipment peers if available: if capex remains strong, the highest-quality execution names should capture share even as the cycle matures.
• Use MU as a confirmation trade, not a hero trade: long only if memory pricing inflects positively over the next 1-2 quarters, which would extend the equipment upcycle and validate the demand stack.
• Avoid chasing META/MSFT on this headline; prefer call spreads over outright longs if entering, since the market likely already reflects much of the infrastructure underwriting and upside depends on monetization, not just spend.